Improving tumor recognition and elimination by NK cells with engineered antibodies

Current immunotherapies for the treatment of cancer exploit engineered T cells, a lymphocyte of the adaptive immune system. An alternative avenue is utilizing the major players of the innate immune system — natural killer (NK) cells. NK cells are innate lymphocytes that express activating receptors, including the NK group 2D (NKG2D) receptor. These NKG2D receptors